Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study
Authors:
Open Access
- 4 March 2018
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 19 (4) , 327-336
Abstract
Background: This subgroup analysis of STELLA-LONG TERM interim data explored the long-term safety and efficacy of ipragliflozin in non-elderly vs. elderly Japanese type 2 diabetes mellitus (T2DM) patients. Research design and methods: STELLA-LONG TERM is an ongoing 3-year prospective surveillance study of Japanese T2DM patients receiving ipragliflozin 50 mg once daily. In this subgroup analysis, patient characteristics, laboratory variables, and adverse drug reactions (ADRs) were compared between non-elderly (P < 0.001). The proportion of patients with hemoglobin A1c (HbA1c) P < 0.001). HbA1c, fasting plasma glucose, and body weight significantly decreased from baseline to 3 and 12 months in both groups (all P < 0.05 vs. baseline). The ADR incidence was 10.83% vs. 10.42% in non-elderly and elderly patients. The incidence of skin complications was 0.98% vs. 1.65% and that of renal disorder was 0.47% vs. 0.95% in non-elderly and elderly patients (both P = 0.003). Conclusions: Ipragliflozin was effective in non-elderly and elderly Japanese T2DM patients in a real-world clinical setting. The incidence of renal disorder and skin complications was significantly higher in elderly vs. non-elderly patients.Keywords
Funding Information
- Astellas Pharma Inc. (N/A)
This publication has 16 references indexed in Scilit:
- A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) studyDiabetes, Obesity and Metabolism, 2014
- Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT studyDiabetology International, 2014
- Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)Diabetology International, 2014
- Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE , a randomized, double‐blind, placebo‐controlled studyDiabetes, Obesity and Metabolism, 2014
- Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN studyDiabetology International, 2014
- The renin-angiotensin system and aging in the kidneyThe Korean Journal of Internal Medicine, 2014
- Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitusJournal of Diabetes Investigation, 2013
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes MellitusCurrent Diabetes Reports, 2012
- SGLT2 inhibitors: molecular design and potential differences in effectKidney International, 2011
- Dry skin in the elderly: Complexities of a common problemClinics in Dermatology, 2011